A Double-blind, Placebo-controlled Study to Determine the Safety and Feasibility of Two Doses of Intravenous (2R, 6R)-Hydroxynorketamine (RR-HNK) in Adults With Obsessive-Compulsive Disorder
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY
The purpose of this study is to understand how RR-HNK works in the brain to bring about a reduction in OCD symptoms.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:
• Ages 18-65
• Meet the criteria for OCD diagnosis
• Failed at least 1 prior trial of standard first-line OCD treatment (e.g. SRI/CBT) or or had refused these treatments for individual reasons
• Agree to the following lifestyle modifications: comply with requirements for fasting prior to --the infusion session, not enroll in any other interventional clinical trials during the duration of the study, and commit to medication study procedures.
• Able to provide informed consent
Locations
United States
California
Stanford University School of Medicine
RECRUITING
Palo Alto
Contact Information
Primary
Daniel Bello, BS
ocdresearch@stanford.edu
650-723-4095
Time Frame
Start Date: 2025-11-01
Estimated Completion Date: 2029-11-30
Participants
Target number of participants: 45
Treatments
Experimental: 0.25 mg/kg RR-HNK
OCD patients in this arm will receive 0.25mg/kg of RR-HNK - one single infusion. EEG and computerized behavioral tests will be acquired before and after infusion.
Experimental: 0.5 mg/kg RR-HNK
OCD patients in this arm will receive 0.5mg/kg of RR-HNK - one single infusion. EEG and computerized behavioral tests will be acquired before and after infusion.
Placebo_comparator: Placebo (Sterile Saline)
OCD patients in this arm will receive sterile saline - one single infusion. EEG and computerized behavioral tests will be acquired before and after infusion.
Related Therapeutic Areas
Sponsors
Leads: Carolyn Rodriguez
Collaborators: National Institutes of Health (NIH)